Clinical trial
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
NCT03612232 is registered in ClinicalTrials.gov with Wuerzburg University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
- Lead sponsor
- Wuerzburg University Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 4, 2019
- Completion date
- April 30, 2025
- Enrollment
- 37 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.